RA
ABBV icon

RoundAngle Advisors’s AbbVie ABBV Stock Holding History

RoundAngle Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.27M Buy
10,445
+38
+0.4% +$8.43K 1.7% 25
2025
Q4 		$2.38M Buy
10,407
+404
+4% +$92K 1.73% 22
2025
Q3 		$2.32M Sell
10,003
-48
-0.5% -$9.78K 1.79% 21
2025
Q2 		$1.87M Buy
10,051
+109
+1% +$20.3K 1.56% 29
2025
Q1 		$2.08M Buy
9,942
+206
+2% +$40K 1.91% 19
2024
Q4 		$1.73M Buy
+9,736
New +$1.79M 1.65% 24

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RoundAngle Advisors's ABBV Position: Q1 2026 in Review

RoundAngle Advisors increased its AbbVie (ABBV) stake by 0.37% in Q1 2026, buying an estimated $8.43K and bringing the position to 10,445 shares worth $2.27M. The position accounts for 1.7% of the portfolio, ranked #25.

RoundAngle Advisors first reported a position in ABBV in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.38M in Q4 2025. 4,104 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • RoundAngle Advisors held 10,445 shares of AbbVie worth $2.27M as of Q1 2026.
  • RoundAngle Advisors bought 38 AbbVie shares in Q1 2026, an estimated $8.43K.
  • AbbVie made up 1.7% of RoundAngle Advisors's portfolio in Q1 2026, its #25 holding.
  • RoundAngle Advisors first reported a position in AbbVie in Q4 2024 and has held it in 6 quarters since.
  • RoundAngle Advisors's AbbVie position peaked at $2.38M in Q4 2025.
  • 4,104 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on RoundAngle Advisors's 13F filing for Q1 2026, filed 8 Apr 2026.